Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.

Pihoker C, Badger TM, Reynolds GA, Bowers CY

The Journal of endocrinology1 Oct 1997Cited by 39 (Europe PMC)

PMID9390009DOI10.1677/joe.0.1550079PepBankPUB-09390009

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with short stature, intranasal GHRP‑2 increased height velocity from 3.7 to 6.1 cm/year at 6 months.
In plain wordsIn children with short stature, intranasal GHRP‑2 was linked to faster growth in height over 6 months, without a control group.
Peptide
GHRP-2
Outcome
IncreaseHeight velocity at 6 months
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 6 monthsAs given in this study (human).
Measurements
Height velocity
3.7 cm/year
baseline
Height velocity
6.1 cm/year
6 months
Source sentences
Summary
Height velocity increased from 3.7 +/- 0.2 cm/year to 6.1 +/- 0.3 cm/year at 6 months
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000901
02HumanNon-randomized trialEfficacy outcome
In children with short stature, intranasal GHRP‑2 produced no significant change in IGF-1 concentrations.
In plain wordsIn children with short stature, intranasal GHRP‑2 did not significantly change IGF-1 levels in the blood.
Peptide
GHRP-2
Outcome
No significant changeSerum IGF-1 concentration
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in IGF-1 or IGF-PB3 concentrations, or in acute GH responses to i.v. or intranasal GHRP-2.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000903
03HumanNon-randomized trialEfficacy outcome
In children with short stature, intranasal GHRP‑2 produced no significant change in IGF-binding protein 3 concentrations.
In plain wordsIn children with short stature, intranasal GHRP‑2 did not significantly change IGF-binding protein 3 levels.
Peptide
GHRP-2
Outcome
No significant changeSerum IGFBP-3 concentration
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in IGF-1 or IGF-PB3 concentrations, or in acute GH responses to i.v. or intranasal GHRP-2.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000904
04HumanNon-randomized trialActivity measurement
In children with short stature, treatment with intranasal GHRP‑2 produced no significant change in the acute GH response to intravenous GHRP‑2.
In plain wordsIn children with short stature, the growth hormone response to an intravenous GHRP‑2 dose did not significantly change during treatment.
Peptide
GHRP-2
Outcome
No significant changeAcute GH response to intravenous GHRP-2 during treatment
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in IGF-1 or IGF-PB3 concentrations, or in acute GH responses to i.v. or intranasal GHRP-2.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000905
05HumanNon-randomized trialActivity measurement
In children with short stature, treatment with intranasal GHRP‑2 produced no significant change in the acute GH response to intranasal GHRP‑2.
In plain wordsIn children with short stature, the growth hormone response to an intranasal GHRP‑2 dose did not significantly change during treatment.
Peptide
GHRP-2
Outcome
No significant changeAcute GH response to intranasal GHRP-2 during treatment
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in IGF-1 or IGF-PB3 concentrations, or in acute GH responses to i.v. or intranasal GHRP-2.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000906
06HumanNon-randomized trialEfficacy outcome
In children with short stature, intranasal GHRP‑2 raised GH-binding protein concentrations from 439 to 688 pmol/l.
In plain wordsIn children with short stature, intranasal GHRP‑2 was linked to higher levels of growth hormone binding protein in the blood.
Peptide
GHRP-2
Outcome
IncreaseGH-binding protein concentration
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 6 monthsAs given in this study (human).
Measurements
GHBP
439 pmol/l
baseline
GHBP
688 pmol/l
after treatment
Source sentences
Summary
GHBP concentrations rose significantly, from 439 +/- 63 pmol/l to 688 +/- 48 pmol/l.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000907
07HumanNon-randomized trialActivity measurement
In children with short stature, every child had a GH response above 10 micrograms/l to intranasal GHRP‑2 at 5-20 micrograms/kg.
In plain wordsIn children with short stature, every child released growth hormone after a single intranasal GHRP‑2 dose.
Peptide
GHRP-2
Outcome
IncreaseAcute GH response to a single intranasal GHRP-2 dose
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-20 micrograms/kg · intranasalAs given in this study (human).
Measurements
GH response
> 10 micrograms/l
intranasal GHRP-2
Source sentences
Summary
Each child in this study also demonstrated a GH response > 10 micrograms/l in response to intranasal GHRP-2, in the dose range of 5-20 micrograms/kg.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000908
08HumanNon-randomized trialActivity measurement
In children with short stature, all children had a GH response above 20 micrograms/l to an acute intravenous bolus of GHRP‑2 at 1 microgram/kg.
In plain wordsIn children with short stature, every child released growth hormone after a single intravenous GHRP‑2 dose.
Peptide
GHRP-2
Outcome
IncreaseAcute GH response to intravenous GHRP-2 bolus
Study
n = 15
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Measurements
GH response
> 20 micrograms/l
i.v. bolus
Source sentences
Summary
The children received testing with GHRH and GHRP-2 as an acute i.v. bolus of 1 microgram/kg; all children in this study demonstrated a GH response > 20 micrograms/l.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000909
09HumanNon-randomized trialSafety outcome
In children with short stature, intranasal GHRP‑2 administration was well tolerated.
In plain wordsIn children with short stature, intranasal GHRP‑2 was well tolerated, according to the study authors.
Peptide
GHRP-2
Outcome
No significant changeTolerability
Study
n = 15
Outcome group
Adverse events · Whole body
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
In this study, intranasal GHRP-2 administration was well tolerated
2 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000910
10HumanNon-randomized trialEfficacy outcome
In children with short stature, height velocity rose from 3.7 to 6.0 cm/year at 18-24 months of intranasal GHRP‑2.
In plain wordsIn six children with short stature, growth in height stayed faster after 18 to 24 months of intranasal GHRP‑2, without a control group.
Peptide
GHRP-2
Outcome
IncreaseHeight velocity at 18-24 months
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5-15 micrograms/kg twice a day for 3 months, then three times a day · intranasal · 18-24 monthsAs given in this study (human).
Measurements
Height velocity
3.7 cm/year
baseline
Height velocity
6 cm/year
18-24 months
Source sentences
Summary
Height velocity increased from 3.7 +/- 0.2 cm/year to 6.1 +/- 0.3 cm/year at 6 months, 6.0 +/- 0.4 cm/year at 18-24 months.
3 context sentences(design, population, supporting numbers)
Summary · context
Fifteen children participated in the study for 6 months; six of the children have participated for 18-24 months.
Summary · context
Fifteen children with short stature participated in this study.
Summary · context
The children were administered intranasal GHRP-2, 5-15 micrograms/kg, twice a day for 3 months, then three times a day.
Report a problemFND-0939000902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms